구조모아 (StructureMoa)항암 chemical structure spider web
방문National Human Genome Research Institute (NHGRI)
Lentiviral Gene Transfer(National Human Genome Research Institute (NHGRI))은 Adenosine Deaminase Deficiency 표적 세포·유전자 치료로, Adenosine Deaminase Deficiency; ADA-SCID 영역에서 개발·상용화 중입니다. 작용기전: targeting, which can enhance tumor-antigen. Phase 1 안전성·PK 탐색 단계입니다. Disease-specific study endpoint: 100. This is a historically controlled, non-randomized Phase I/II clinical trial to assess the safety and e. 차별점: novel serum-free CHO suspension cell lines with enhanced CPR and/or defined CYP activity as a promising "humanised" in vitro.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
Adenosine Deaminase Deficiency
Adenosine Deaminase Deficiency; ADA-SCID
Active
2026-08-19
Data Confidence · Medium
Development Signal · Watch
Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Faci
lentiviral gene transfer to downregulate orexin expression in male and female young rats t
Humanized mouse models are essential for evaluating the engraftment capacity and genetic integrity of gene-mo
novel serum-free CHO suspension cell lines with enhanced CPR and/or defined CYP activity as a promising "humanised" in vitro
targeting, which can enhance tumor-antigen
immune-mediated diseases including immune dysregulation polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome
payload protein, provided an additional >10-fold increase in overall factor VIII output in mice and non-human primates
PD-1/PD-L1 signaling low
downregulation
구조화 데이터
xenograft-versus-host disease (xeno-GvHD) and FOXP3-deficient IPEX-like humanised mouse
rat
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
National Human Genome Research Institute (NHGRI)
Lentiviral Gene Transfer(National Human Genome Research Institute (NHGRI))은 Adenosine Deaminase Deficiency 표적 세포·유전자 치료로, Adenosine Deaminase Deficiency; ADA-SCID 영역에서 개발·상용화 중입니다. 작용기전: targeting, which can enhance tumor-antigen. Phase 1 안전성·PK 탐색 단계입니다. Disease-specific study endpoint: 100. This is a historically controlled, non-randomized Phase I/II clinical trial to assess the safety and e. 차별점: novel serum-free CHO suspension cell lines with enhanced CPR and/or defined CYP activity as a promising "humanised" in vitro.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
Adenosine Deaminase Deficiency
Adenosine Deaminase Deficiency; ADA-SCID
Active
2026-08-19
Data Confidence · Medium
Development Signal · Watch
Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Faci
lentiviral gene transfer to downregulate orexin expression in male and female young rats t
Humanized mouse models are essential for evaluating the engraftment capacity and genetic integrity of gene-mo
novel serum-free CHO suspension cell lines with enhanced CPR and/or defined CYP activity as a promising "humanised" in vitro
targeting, which can enhance tumor-antigen
immune-mediated diseases including immune dysregulation polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome
payload protein, provided an additional >10-fold increase in overall factor VIII output in mice and non-human primates
PD-1/PD-L1 signaling low
downregulation
구조화 데이터
xenograft-versus-host disease (xeno-GvHD) and FOXP3-deficient IPEX-like humanised mouse
rat
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.